Cytogen to roll-out ProstaScint at 65 sites following Oct. 28 approval.
CYTOGEN PROSTASCINT PROCEDURE COST WILL BE $1,400 TO $2,000, the company estimated following FDA approval of the prostate cancer diagnostic imaging agent Oct. 28. ProstaScint (capromab pendetide) will be introduced at a cost of $700 for a 1 mL vial of the unlabeled murine monoclonal antibody. The BLA for ProstaScint was filed on March 13, 1995.
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth